Effect of treatment schedule on the interaction of cisplatin and radiation in human lung cancer cells

Radiation Research

Volumn 167, Issue 6, 2007, Pages 637-644

  Asaka Amano, Yoshiko ^a   Takiguchi, Yuichi ^a   Yatomi, Mari ^a   Kurosu, Katsushi ^a   Kasahara, Yasunori ^a   Tanabe, Nobuhiro ^a   Tatsumi, Koichiro ^a   Kuriyama, Takayuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LINE; CELL THERAPY; DRUG EXPOSURE; HUMAN; HUMAN CELL; IRRADIATION; LUNG CANCER; PRIORITY JOURNAL; RADIATION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TIME; ADJUVANT THERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; LUNG TUMOR; PATHOLOGY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION RESPONSE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT;

EID: 34447536726     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR0739.1     Document Type: Article

References (41)

1. G. G. Steel and M. J. Peckham, Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85-91 (1979).
2. J. L. Millar, N. M. Blackett and B. N. Hudspith, Enhanced postirradiation recovery of the haemopoietic system in animals pretreated with a variety of cytotoxic agents. Cell Tissue Kinet. 11, 543-553 (1978).
3. L. A. Zwelling and K. W. Kohn, Mechanism of action of cis-dichlorodiammineplatinum(II). Cancer Treat. Rep. 63, 1439-1444 (1979).
4. M. M. Elkind, DNA damage and cell killing. Cause and effect? Cancer 56, 2351-2363 (1985).
5. Z. H. Siddik, Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
6. A. S. Lichter and T. S. Lawrence, Recent advances in radiation oncology. New Engl. J. Med. 332, 371-379 (1995).
7. A. Maity, G. D. Kao, R. J. Muschel and W. G. McKenna, Potential molecular targets for manipulating the radiation response. Int. J. Radiat. Oncol. Biol. Phys. 37, 639-653 (1997).
8. P. Fei and W. S. El-Deiry, P53 and radiation responses. Oncogene 22, 5774-5783 (2003).
9. E. B. Douple and R. C. Richmond, Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br. J. Cancer 37 (Suppl.), 98-102 (1978).
10. M. V. Alvarez, G. Cobreros, A. Heras and M. C. Lopez Zumel, Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer. Br. J. Cancer 37 (Suppl.), 68-72 (1978).
11. A. C. Begg, P. J. van der Kolk, L. Dewit and H. Bartelink, Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 50, 871-884 (1986).
12. A. A. Geldof and B. J. Slotman, Radiosensitizing effect of cisplatin in prostate cancer cell lines. Cancer Lett. 101, 233-239 (1996).
13. S. Nakamoto, N. Mitsuhashi, T. Takahashi, H. Sakurai and H. Niibe, An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radio sensitivities in vitro. Int. J. Radiat. Biol. 70, 747-753 (1996).
14. M. Tanabe, D. Godat and R. F. Kallman, Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse. Int. J. Radiat. Oncol. Biol. Phys. 13, 1523-1532 (1987).
15. P. R. Twentyman, R. F. Kallman and J. M. Brown, The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors. III. Cis-diamminedichloroplatinum. Int. J. Radiat. Oncol. Biol. Phys. 5, 1365-1367 (1979).
16. J. Overgaard and A. R. Khan, Selective enhancement of radiation response in a C3H mammary carcinoma by cisplatin. Cancer Treat. Rep. 65, 501-503 (1981).
17. J. T. Leith, E. S. Lee, A. J. Vayer, Jr., D. L. Dexter and A. S. Glicksman, Enhancement of the responses of human colon adenocarcinoma cells to X-irradiation and cis-platinum by N-methylformamide (NMF). Int. J. Radiat. Oncol. Biol. Phys. 11, 1971-1976 (1985).
18. W. Ziegler and J. M. Kopp, The effect of combined treatment of HeLa cells with cisplatin and irradiation upon survival and recovery from radiation damage. Radiother. Oncol. 8, 71-78 (1987).
19. M. Flentje, M. Eble, U. Haner, S. Trinh and M. Wannenmacher, Additive effects of cisplatin and radiation in human tumor cells under oxic conditions. Radiother. Oncol. 24, 60-63 (1992).
20. E. B. Douple and R. C. Richmond, Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Int. J. Radiat. Oncol. Biol. Phys. 5, 1369-1372 (1979).
21. 125I radiation in a murine brachytherapy model. Int. J. Radiat. Oncol. Biol. Phys. 10, 1471-1472 (1984).
22. R. Gorodetsky, X. Mou, M. R. Pfeffer, T. Peretz, F. Levy-Agababa and A. M. Vexler, Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines. Isr. J. Med. Sci. 31, 95-100 (1995).
23. R. Gorodetsky, F. Levy-Agababa, X. Mou and A. M. Vexler, Combination of cisplatin and radiation in cell culture: Effect of duration of exposure to drug and timing of irradiation. Int. J. Cancer 75, 635-642 (1998).
24. L. Dewit, Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data. Int. J. Radiat. Oncol. Biol. Phys. 13, 403-426 (1987).
25. H. Bartelink, R. F. Kallman, D. Rapacchietta and G. A. Hart, Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiother. Oncol. 6, 61-74 (1986).
26. A. C. Begg, S. Bohlken and H. Bartelink, The effect of cisplatin on the repair of radiation damage in RIF1 mouse tumours in vivo. Radiother. Oncol. 15, 79-91 (1989).
27. H. J. Groen, S. Sleijfer, C. Meijer, H. H. Kampinga, A. W. Konings, E. G. De Vries and N. H. Mulder, Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br. J. Cancer 72, 1406-1411 (1995).
28. C. Schaake-Koning, W. van den Bogaert, O. Dalesio, J. Festen, J. Hoogenhout, P. van Houtte, A. Kirkpatrick, M. Koolen and B. Maat, Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl. J. Med. 326, 524-530 (1992).
29. Y. Takiguchi, R. Uruma, Y. Asaka-Amano, K. Kurosu, Y. Kasahara, N. Tanabe, K. Tatsumi, T. Uno, H. Itoh and T. Kuriyama, Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma. Int. J. Clin. Oncol. 10, 418-424 (2005).
30. G. W. Barendsen, Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int. J. Radiat. Oncol. Biol. Phys. 8, 1981-1997 (1982).
31. G. S. Hagopian, G. B. Mills, A. R. Khokhar, R. C. Bast, Jr. and Z. H. Siddik, Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans- diacetato)(dichloro)-platinum(IV). Clin. Cancer Res. 5, 655-663 (1999).
32. M. G. Ormerod, R. M. Orr and J. H. Peacock, The role of apoptosis in cell killing by cisplatin: A flow cytometric study. Br. J. Cancer 69, 93-100 (1994).
33. W. K. Sinclair, Cyclic x-ray responses in mammalian cells in vitro. Radiat. Res. 33, 620-643 (1968).
34. 2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia. Radiat. Res. 164, 627-634 (2005).
35. P. R. Andreassen, O. D. Lohez and R. L. Margolis, G2 and spindle assembly checkpoint adaptation, and tetraploidy arrest: Implications for intrinsic and chemically induced genomic instability. Mutat. Res. 532, 245-253 (2003).
36. E. I. Miranda, C. Santana, E. Rojas, S. Hernandez, P. Ostrosky-Wegman and A. Garcia-Carranca, Induced mitotic death of HeLa cells by abnormal expression of c-H-ras. Mutat. Res. 349, 173-182 (1996).
37. M. Watanabe, M. Hitomi, K. van der Wee, F. Rothenberg, S. A. Fisher, R. Zucker, K. K. Svoboda, E. C. Goldsmith, K. M. Heiskanen and A. L. Nieminen, The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs. Microsc. Microanal. 8, 375-391 (2002).
38. G. L. Yount, D. A. Haas-Kogan, K. S. Levine, K. D. Aldape and M. A. Israel, Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: Implications for combined modality therapy. Cancer Res. 58, 3819-3825 (1998).
39. M. Fujita, T. Fujita, T. Kodama, T. Tsuchida and K. Higashino, The inhibitory effect of cisplatin in combination with irradiation on lung tumor cell growth is due to induction of tumor cell apoptosis. Int. J. Oncol. 17, 393-397 (2000).
40. M. Fukuoka, K. Kitajima, M. Takada, M. Negoro, S. Matsui, K. Kusunoki, Y. Ryu, S. Sakai, N. Takifuji and T. Kimura, Therapeutic efficacy and pharmacokinetics of cisplatin in patients with non-small cell lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 25, 44-49 (1987). [in Japanese]
41. K. J. Himmelstein, T. F. Patton, R. J. Belt, S. Taylor, A. J. Repta and L. A. Sternson, Clinical kinetics on intact cisplatin and some related species. Clin. Pharmacol. Ther. 29, 658-664 (1981).